Recently, Jichuan Pharmaceutical's independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children's constipation , enriches the company's product portfolio, and enhances its core competitiveness in the pediatric field.

01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation

Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children's Medical Center, Capital Medical University), and clinical trials have verified its effects of strengthening the spleen, regulating qi, and relieving constipation. It provides an innovative option for clinical medication in the field of pediatric digestion.

02 Accelerate innovation and research and development to solidify advantages in pediatric fields

As one of the pharmaceutical companies in China with the most pediatric varieties and dosage forms, Jichuan Pharmaceutical has been deeply involved in the field of pediatrics for many years. It has successively created a number of branded products suitable for children, such as Pudilan Anti-inflammatory Oral Liquid, Xiaoer Chiqiao Qingre Granules (Tongbei), Jianwei Xiaoshi Oral Liquid, Huanglong Zhike Granules, and Protein Succinate Ferric Oral Solution (Shengxueyuan), which have gained widespread market recognition.

Building upon its existing pediatric product portfolio, the company has actively pursued secondary development of its marketed products and research and development of innovative and high-end chemical drugs, achieving remarkable results. Among these achievements, Xiao Er Chi Qiao Qing Re Syrup (Jin Tong Bei) became the first improved traditional Chinese medicine to be approved for marketing under the new "Drug Registration Management Measures" ; the novel second-generation antihistamine fexofenadine hydrochloride dry suspension (Min Fei Le) is the first domestically marketed dry suspension form of fexofenadine , providing a superior dosage form option for children's allergy medications; and in April of this year, Jichuan Pharmaceutical's Class 1.1 traditional Chinese medicine new drug, Chai Ge Antipyretic Oral Liquid, had its marketing application accepted by the National Medical Products Administration , marking another significant step forward in innovative research and development.

The successful approval of the pediatric laxative granules is another landmark achievement for Jichuan Pharmaceutical, demonstrating its continued commitment to the pediatric field and highlighting the company's core driving force for innovation and strategic implementation. Moving forward, Jichuan Pharmaceutical will continue to uphold its vision of "creating a happy and fulfilling life experience," taking the protection of public health as its mission. Leveraging its comprehensive R&D and production system, the company will increase investment in innovative drug development, accelerate the transformation of innovative achievements, and expedite the accessibility of high-quality products for patients, thus safeguarding the health of the nation.

https://news.yaozh.com/archive/48785.html